Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of December 2015, specifically dated December 17, 2015. The registrant is a foreign private issuer based in Petach-Tikva, Israel, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
The primary material event reported is the grant of a patent by the Japan Patent Office for the company's product candidate, CF101. The patent is titled "A3 adenosine receptor agonists for the reduction of intraocular pressure."
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future performance, or specific risk factors beyond the context of the patent grant. No unusual items or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the scope and validity of the Japan Patent Office grant for CF101 regarding intraocular pressure reduction.
- Review the attached press release (Exhibit 99.1) for details on the patent's commercial implications.
- Check subsequent filings for any financial impact or strategic shifts resulting from this intellectual property milestone.